Xenon Pharmaceuticals/$XENE
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Ticker
$XENE
Sector
Primary listing
Employees
364
Headquarters
Burnaby, Canada
Website
XENE Metrics
BasicAdvanced
$5.2B
-
-$4.36
0.94
-
Price and volume
Market cap
$5.2B
Beta
0.94
52-week high
$63.95
52-week low
$26.74
Average daily volume
1.7M
Financial strength
Current ratio
13.415
Quick ratio
13.167
Long term debt to equity
1.102
Total debt to equity
1.366
Profitability
EBITDA (TTM)
-370.527
Gross margin (TTM)
-3,912.51%
Net profit margin (TTM)
-4,612.13%
Operating margin (TTM)
-4,974.27%
Effective tax rate (TTM)
-0.29%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-32.58%
Return on equity (TTM)
-51.76%
Valuation
Price to revenue (TTM)
577.606
Price to book
7.52
Price to tangible book (TTM)
7.52
Price to free cash flow (TTM)
-15.476
Free cash flow yield (TTM)
-6.46%
Free cash flow per share (TTM)
-3.532
Growth
Earnings per share change (TTM)
45.09%
3-year revenue growth (CAGR)
-7.36%
10-year revenue growth (CAGR)
-7.05%
3-year earnings per share growth (CAGR)
28.21%
10-year earnings per share growth (CAGR)
14.75%
What the Analysts think about XENE
Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
XENE Financial Performance
Revenues and expenses
XENE Earnings Performance
Company profitability
XENE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals (XENE) has a market cap of $5.2B as of March 17, 2026.
What is the P/E ratio for Xenon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of March 17, 2026.
Does Xenon Pharmaceuticals stock pay dividends?
No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Xenon Pharmaceuticals dividend payment date?
Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.